Xeris Biopharma Holdings, Inc. (XERS) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
XERS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Xeris Biopharma Holdings, Inc. (XERS) trades at a price-to-earnings ratio of 2071.9x, with a stock price of $6.63 and trailing twelve-month earnings per share of $0.07.
The current P/E is 2129% above its 5-year average of 92.9x. Over the past five years, XERS's P/E has ranged from a low of 92.9x to a high of 92.9x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, XERS trades at a 9181% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, XERS commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XERS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
XERS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 26.7 | - | -22% | |
| $2B | 36.3 | 4.85 | +1883%Best | |
| $5B | 62.3 | - | -33% | |
| $4B | 62.4 | - | +158% | |
| $203B | 12.7Lowest | 0.61Best | +2% | |
| $921B | 42.5 | 1.47 | +96% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
XERS Historical P/E Data (2026–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $5.80 | $0.06 | 92.9x | +0% |
Average P/E for displayed period: 92.9x
See XERS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XERS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XERS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXERS — Frequently Asked Questions
Quick answers to the most common questions about buying XERS stock.
Is XERS stock overvalued or undervalued?
XERS trades at 2071.9x P/E, above its 5-year average of 92.9x. The 100th percentile ranking indicates a premium to historical valuation.
How does XERS's valuation compare to peers?
Xeris Biopharma Holdings, Inc. P/E of 2071.9x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is XERS's PEG ratio?
XERS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.